S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
NASDAQ:FBRX

Forte Biosciences (FBRX) Stock Price, News & Analysis

$0.72
+0.04 (+5.85%)
(As of 03/1/2024 ET)
Today's Range
$0.69
$0.73
50-Day Range
$0.49
$0.85
52-Week Range
$0.38
$1.29
Volume
136,822 shs
Average Volume
50,808 shs
Market Capitalization
$26.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Forte Biosciences MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Forte Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$52,112 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.58) to ($0.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.07 out of 5 stars

Medical Sector

814th out of 951 stocks

Pharmaceutical Preparations Industry

355th out of 416 stocks


FBRX stock logo

About Forte Biosciences Stock (NASDAQ:FBRX)

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

FBRX Stock Price History

FBRX Stock News Headlines

Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX)
Forte Biosciences Inc Ordinary Shares
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Forte Biosciences Inc Ordinary Shares FBRX
Forte Biosciences GAAP EPS of -$0.26
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Camac Fund Now Owns 4.3% of Forte Biosciences
FBRX Forte Biosciences, Inc.
See More Headlines
Receive FBRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/18/2021
Today
3/02/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FBRX
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Net Income
$-13,880,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.91 per share

Miscellaneous

Free Float
32,509,000
Market Cap
$26.29 million
Optionable
Optionable
Beta
0.48
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














FBRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Forte Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FBRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FBRX, but not buy additional shares or sell existing shares.
View FBRX analyst ratings
or view top-rated stocks.

How have FBRX shares performed in 2024?

Forte Biosciences' stock was trading at $0.8217 at the beginning of 2024. Since then, FBRX shares have decreased by 11.9% and is now trading at $0.7236.
View the best growth stocks for 2024 here
.

Are investors shorting Forte Biosciences?

Forte Biosciences saw a increase in short interest in February. As of February 15th, there was short interest totaling 80,400 shares, an increase of 62.4% from the January 31st total of 49,500 shares. Based on an average daily volume of 38,400 shares, the days-to-cover ratio is currently 2.1 days.
View Forte Biosciences' Short Interest
.

When is Forte Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our FBRX earnings forecast
.

How were Forte Biosciences' earnings last quarter?

Forte Biosciences, Inc. (NASDAQ:FBRX) announced its earnings results on Thursday, November, 18th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.18.

What other stocks do shareholders of Forte Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN).

Who are Forte Biosciences' major shareholders?

Forte Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Cable Car Capital LLC (5.59%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Paul A Wagner and Paul A Wagner.
View institutional ownership trends
.

How do I buy shares of Forte Biosciences?

Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FBRX) was last updated on 3/3/2024 by MarketBeat.com Staff